A Multi-center, Open Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Clinical Efficacy of BAT7104 Injection in Patients with Advanced Malignant Tumors
Latest Information Update: 13 Dec 2024
At a glance
- Drugs BAT 7104 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Bio-Thera Solutions
Most Recent Events
- 10 Dec 2024 Planned End Date changed from 20 Jan 2024 to 20 Dec 2024.
- 10 Dec 2024 Planned primary completion date changed from 20 Jan 2024 to 20 Dec 2024.
- 13 May 2022 New trial record